Cargando…

Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies

Recently identified broadly neutralizing antibodies (bnAbs) show great potential for clinical interventions against HIV-1 infection. However, resistant strains may impose substantial challenges. Here, we report on the identification and characterization of a panel of HIV-1 strains with broad and pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Panpan, Wang, Han, Fang, Mengqi, Li, Yangyang, Wang, Hua, Shi, Shasha, Li, Zihao, Wu, Jiapeng, Han, Xiaoxu, Shi, Xuanling, Shang, Hong, Zhou, Tongqing, Zhang, Linqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592578/
https://www.ncbi.nlm.nih.gov/pubmed/31194843
http://dx.doi.org/10.1371/journal.ppat.1007819
Descripción
Sumario:Recently identified broadly neutralizing antibodies (bnAbs) show great potential for clinical interventions against HIV-1 infection. However, resistant strains may impose substantial challenges. Here, we report on the identification and characterization of a panel of HIV-1 strains with broad and potent resistance against a large number of bnAbs, particularly those targeting the CD4-binding site (CD4bs). Site-directed mutagenesis revealed that several key epitope mutations facilitate resistance and are located in the inner domain, loop D, and β23/loop V5/β24 of HIV-1 gp120. The resistance is largely correlated with binding affinity of antibodies to the envelope trimers expressed on the cell surface. Our results therefore demonstrate the existence of broadly resistant HIV-1 strains against CD4bs neutralizing antibodies. Treatment strategies based on the CD4bs bnAbs must overcome such resistance to achieve optimal clinical outcomes.